NL8900574A - Antivirale en immunostimulerende farmaceutische preparaten en werkwijze voor de bereiding ervan. - Google Patents
Antivirale en immunostimulerende farmaceutische preparaten en werkwijze voor de bereiding ervan. Download PDFInfo
- Publication number
- NL8900574A NL8900574A NL8900574A NL8900574A NL8900574A NL 8900574 A NL8900574 A NL 8900574A NL 8900574 A NL8900574 A NL 8900574A NL 8900574 A NL8900574 A NL 8900574A NL 8900574 A NL8900574 A NL 8900574A
- Authority
- NL
- Netherlands
- Prior art keywords
- acid
- preparation
- lysine
- active ingredients
- fatty acids
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 24
- 230000000840 anti-viral effect Effects 0.000 title claims description 13
- 230000003308 immunostimulating effect Effects 0.000 title claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 46
- 239000004472 Lysine Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 235000019766 L-Lysine Nutrition 0.000 claims description 21
- 150000004665 fatty acids Chemical class 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 241000251468 Actinopterygii Species 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- -1 ammonia cation Chemical class 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 1
- 229940013317 fish oils Drugs 0.000 claims 1
- 229960003646 lysine Drugs 0.000 description 19
- 241000700605 Viruses Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HZRUTVAFDWTKGD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrate Chemical compound O.NCCCC[C@H](N)C(O)=O HZRUTVAFDWTKGD-JEDNCBNOSA-N 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 5
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229960003104 ornithine Drugs 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- OVGORFFCBUIFIA-UHFFFAOYSA-N Fenipentol Chemical compound CCCCC(O)C1=CC=CC=C1 OVGORFFCBUIFIA-UHFFFAOYSA-N 0.000 description 1
- 241000276438 Gadus morhua Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021460 Immunodeficiency syndromes Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019516 cod Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU881132A HU209973B (en) | 1988-03-09 | 1988-03-09 | Process for production of antiviral and immunstimular pharmaceutical composition |
| HU113288 | 1988-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8900574A true NL8900574A (nl) | 1989-10-02 |
Family
ID=10952974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8900574A NL8900574A (nl) | 1988-03-09 | 1989-03-09 | Antivirale en immunostimulerende farmaceutische preparaten en werkwijze voor de bereiding ervan. |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JPH01316316A (hu) |
| KR (1) | KR890014103A (hu) |
| BE (1) | BE1002890A3 (hu) |
| CA (1) | CA1334576C (hu) |
| CH (1) | CH678918A5 (hu) |
| DE (1) | DE3907649C2 (hu) |
| FI (1) | FI94591C (hu) |
| FR (1) | FR2628324B1 (hu) |
| GB (1) | GB2216418B (hu) |
| HU (1) | HU209973B (hu) |
| IT (1) | IT1229562B (hu) |
| LU (1) | LU87471A1 (hu) |
| NL (1) | NL8900574A (hu) |
| SE (1) | SE8900828L (hu) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU210122B (en) * | 1988-03-23 | 1995-02-28 | Biorex Kutato Fejlesztoe Kft | Process for production of composition against thromboembolytic conditions of circulating system and heart |
| JPH04279523A (ja) * | 1991-01-11 | 1992-10-05 | Nisshin Flour Milling Co Ltd | 免疫賦活油脂加工品 |
| GB9304746D0 (en) * | 1993-03-09 | 1993-04-28 | Scotia Holdings Plc | Treatment of viral infections |
| EP0690709A1 (en) * | 1993-03-26 | 1996-01-10 | DINU, Constantin Romulus | Pharmaceutical composition for the treatment of certain viruses and autoimmune diseases and the procedure of its preparation |
| GB9318611D0 (en) * | 1993-09-08 | 1993-10-27 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| WO1995009622A1 (en) * | 1993-10-06 | 1995-04-13 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| IT1264987B1 (it) * | 1993-12-14 | 1996-10-17 | Prospa Bv | Sali di un acido grasso poliinsaturo e formulazioni farmaceutiche che li contengono |
| AUPM906594A0 (en) * | 1994-10-26 | 1994-11-17 | Peptide Technology Limited | Synthetic polyunsaturated fatty acid analogues |
| DE19503993A1 (de) * | 1995-02-08 | 1996-08-14 | Johann Friedrich Dr Med Desaga | Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen |
| US5639858A (en) * | 1995-03-22 | 1997-06-17 | Tularik, Inc. | Human signal transducer and binding assays |
| AU5002196A (en) * | 1995-03-28 | 1996-10-16 | Novo Nordisk A/S | Immunosuppressive agents |
| HU227588B1 (hu) * | 2004-12-03 | 2011-09-28 | Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft | Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény |
| CN101939000A (zh) * | 2007-12-17 | 2011-01-05 | 佛罗里达大学研究基金会有限公司 | 用于治疗病理性眼部血管增生的物质和方法 |
| FR3031451B1 (fr) * | 2015-01-13 | 2018-03-23 | Greentech | Sel d'un triglyceride, preparation et utilisations |
| US12115260B2 (en) | 2016-05-25 | 2024-10-15 | Evonik Operations Gmbh | Tablets with high active ingredient content of omega-3 fatty acid amino acid salts |
| EP3248467A1 (de) * | 2016-05-25 | 2017-11-29 | Evonik Technochemie GmbH | Verfahren zur herstellung einer zusammensetzung enthaltend omega-3-fettsäure-l-lysin-salze |
| EP3648748A1 (en) | 2017-07-06 | 2020-05-13 | Evonik Operations GmbH | Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts |
| CA3072658C (en) | 2017-08-15 | 2023-01-24 | Evonik Operations Gmbh | Tablets with high active ingredient content of omega-3 fatty acid amino acid salts |
| US20220287345A1 (en) | 2019-08-08 | 2022-09-15 | Evonik Operations Gmbh | Solubility enhancement of poorly soluble actives |
| KR20220044542A (ko) | 2019-08-08 | 2022-04-08 | 에보니크 오퍼레이션즈 게엠베하 | 다중불포화 지방산 염의 제조를 위한 다운스트림 공정 |
| DE102022003441A1 (de) | 2022-09-17 | 2024-03-28 | Jutta Ibrahim | Nahrungsergänzungsmittel Omega3 und essentielle Aminosäure(n) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1256162A (en) * | 1968-08-16 | 1971-12-08 | Braun Fa B | Improvements in and relating to liquid products for intravenous administration |
| FR2215212B1 (hu) * | 1973-01-18 | 1976-03-05 | Seperic Ch | |
| FR2508797B1 (fr) * | 1981-07-03 | 1986-03-14 | Charles Chany | Medicament comprenant le produit de la reaction d'un acide carboxylique en c1 a c6 sur un amino-acide basique |
| GB2118437B (en) * | 1982-03-01 | 1984-12-12 | Efamol Ltd | Composition for treating alcoholism |
| US4513008A (en) * | 1982-07-30 | 1985-04-23 | The Vinoxen Company, Inc. | Virucidal compositions and therapy |
| DE3229956A1 (de) * | 1982-08-12 | 1984-02-16 | Erichsen, Friedrich Karl, Dr., 2351 Schillsdorf | Arzneimittel mit cytostatischer wirkung |
| DE3514328C1 (de) * | 1985-04-19 | 1986-09-11 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, 6900 Heidelberg | Verwendung von L-Ornithin bei der selektiven Hemmung von cytotoxischen T-Lymphozyten-Effektorzellen |
| WO1988001861A1 (en) * | 1986-09-17 | 1988-03-24 | Baxter Travenol Laboratories, Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases |
| DE3878812T2 (de) * | 1987-02-20 | 1993-07-22 | Shriners Hospitals For Cripple | Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen. |
| DE3726299A1 (de) * | 1987-06-26 | 1989-02-23 | Dietl Hans | Fettemulsion zur intravenoesen anwendung |
-
1988
- 1988-03-09 HU HU881132A patent/HU209973B/hu unknown
-
1989
- 1989-03-06 CH CH819/89A patent/CH678918A5/de not_active IP Right Cessation
- 1989-03-09 JP JP1055242A patent/JPH01316316A/ja active Pending
- 1989-03-09 SE SE8900828A patent/SE8900828L/xx not_active Application Discontinuation
- 1989-03-09 IT IT8919704A patent/IT1229562B/it active
- 1989-03-09 BE BE8900254A patent/BE1002890A3/fr not_active IP Right Cessation
- 1989-03-09 FR FR8903085A patent/FR2628324B1/fr not_active Expired - Fee Related
- 1989-03-09 LU LU87471A patent/LU87471A1/fr unknown
- 1989-03-09 KR KR1019890002920A patent/KR890014103A/ko not_active Application Discontinuation
- 1989-03-09 NL NL8900574A patent/NL8900574A/nl not_active Application Discontinuation
- 1989-03-09 GB GB8905385A patent/GB2216418B/en not_active Expired - Fee Related
- 1989-03-09 FI FI891145A patent/FI94591C/fi not_active IP Right Cessation
- 1989-03-09 DE DE3907649A patent/DE3907649C2/de not_active Expired - Fee Related
- 1989-03-09 CA CA000593270A patent/CA1334576C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FI891145A0 (fi) | 1989-03-09 |
| CH678918A5 (hu) | 1991-11-29 |
| DE3907649A1 (de) | 1989-09-28 |
| FI94591B (fi) | 1995-06-30 |
| KR890014103A (ko) | 1989-10-21 |
| HUT60432A (en) | 1992-09-28 |
| FR2628324A1 (fr) | 1989-09-15 |
| IT1229562B (it) | 1991-09-04 |
| FR2628324B1 (fr) | 1994-05-27 |
| FI891145L (fi) | 1989-09-10 |
| SE8900828D0 (sv) | 1989-03-09 |
| GB2216418A (en) | 1989-10-11 |
| GB2216418B (en) | 1991-12-11 |
| DE3907649C2 (de) | 1996-07-11 |
| HU209973B (en) | 1995-01-30 |
| CA1334576C (en) | 1995-02-28 |
| BE1002890A3 (fr) | 1991-07-16 |
| IT8919704A0 (it) | 1989-03-09 |
| SE8900828L (sv) | 1989-09-10 |
| LU87471A1 (fr) | 1990-10-02 |
| JPH01316316A (ja) | 1989-12-21 |
| GB8905385D0 (en) | 1989-04-19 |
| FI94591C (fi) | 1995-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8900574A (nl) | Antivirale en immunostimulerende farmaceutische preparaten en werkwijze voor de bereiding ervan. | |
| Blinkova et al. | Biological activity of Spirulina Zh Mikrobiol Epidemiol Immunobiol. 2001 Mar-Apr;(2): 114–8. Review. In this review information of Spirulina platensis (SP), a blue-green alga (photosynthesizing cyanobacterium) having diverse biological activity is presented. Due to high content of highly | |
| RAICA JR et al. | Blood cell transaminase activity in human vitamin B6deficiency | |
| EP0355131A1 (en) | Acyl deoxyribonucleoside derivatives and uses thereof | |
| Junquero et al. | Inhibition of cytokine‐induced nitric oxide production by transforming growth factor‐beta 1 in human smooth muscle cells. | |
| CS251060B2 (en) | 9-(hydroxyalkyl)purines' derivatives salts production method | |
| NL8900573A (nl) | Nieuwe zout-type verbindingen, farmaceutische preparaten met dergelijke verbindingen erin en werkwijze voor de bereiding ervan. | |
| Suzuki et al. | Studies on antiviral agents. IV. Biological activity of tenuazonic acid derivatives. | |
| US5824664A (en) | Suppression of HIV expression by organic thiophosphate | |
| Elmore et al. | Kinetics and mechanism of catalysis by proteolytic enzymes: The kinetics of hydrolysis of derivatives of l-lysine and S-(β-aminoethyl)-l-cysteine (thialysine) by bovine trypsin | |
| Sacklin et al. | Effect of DDT on enzymatic oxidation and phosphorylation | |
| US5543300A (en) | Method and composition for determining the immunological activity of bioactive substances | |
| Hughes-Fulford et al. | Effects of dimethyl prostaglandin A1 on herpes simplex virus and human immunodeficiency virus replication | |
| Segel et al. | Amino acid transport in human lymphocytes: distinctions in the enhanced uptake with PHA treatment or amino acid deprivation | |
| Watanabe et al. | Novel anti-respiratory syncytial (RS) viral compounds: benzodithiin derivatives | |
| Schales | Effect of additions to ACD blood on erythrocyte preservation. | |
| IT9048102A1 (it) | Derivati oligopeptidici dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono | |
| CA2176392C (en) | Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection | |
| US6140367A (en) | Use of ethylene diamine disuccinate for preparing a medicament with antiviral properties | |
| Neubauer | Antilymphocytic Factor Derived from a Herpesvirus saimiri Lymphoid Tumor Cell Line¹ | |
| Verini et al. | Antiviral activity of a pyrazino-pyrazine derivative. | |
| RU2012335C1 (ru) | Ингибитор вируса простого герпеса | |
| Winslow et al. | DMP450, a new cyclic urea inhibitor of HIV protease with potent in vitro antiviral activity | |
| Deasy et al. | in the Dubnoff apparatus under 95 per cent O2 and 5 per cent CO2 at 37.5 C. for lengths of time indicated below, with a rocking rate of 100 cycles per | |
| Porzsolt et al. | Measurement of Cell Mediated Cytotoxicity by Post‐Labeling Surviving Target Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BV | The patent application has lapsed |